

DRAFT | June 2019

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	▼	X
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	▼	X
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	▼	X
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	▼	X
Animal observed in or captured from the field: Provide species, sex and age where possible	▼	X
Model organisms: Provide Accession number in repository (where relevant) OR RRID	▼	X
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	▼	X
Microbes: provide species and strain, unique accession number if available, and source	▼	X
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	(2020) No. (2020-04-09).	
Provide statement confirming informed consent obtained from study participants.	The questionnaire of this study was conducted anonymously, and it was informed that the study results will be analyzed as a whole. Participants decided to take part in the questionnaire voluntarily and answer according to the actual situation. (lines 131-133)	
Report on age and sex for all study participants.	20.6% of the participants were aged from 18 to 30, 62.7% were aged from 31 to 40, and 16.7% were over 40. 26.1% of the study participants were male and 73.9% were female. (lines 191)	

删除的内容: No antibodies used.

删除的内容: No cell lines used.

删除的内容: No cultures used.

删除的内容: No Laboratory animals used.

删除的内容: No laboratory animals used.

删除的内容: No model organisms used.

删除的内容: No plants used.

删除的内容: No microbes used.

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	▼	X
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	▼	X
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.	▼	X
Sample size determination		X
Randomisation		X
Blinding		X
Inclusion/exclusion criteria		X
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	▼	X
Define whether data describe technical or biological replicates		X
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	The institution granting ethical approval is Medical Ethics Committee of School of Public Health, Jilin University, and the approval reference number is (2020) No. (2020-04-09).	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	▼	X
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	▼	X
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	▼	X

删除的内容: No trial.

删除的内容: No laboratory investigation.

删除的内容: No experimental study.

删除的内容: No laboratory study.

删除的内容: No animals studied.

删除的内容: No field samples.

删除的内容: No dual use research.

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	▼	X

删除的内容: No data excluded.

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Our study used χ^2 tests to compare bivariate associations between each of the disordered categorical variables and the categorized four level outcome variables. And Kruskal-Wallis tests were used to analyze the ordered categorical variables and the four level outcome variables. Then adopted ANOVA in order to analyze comparisons of continuous measures in the four groups. Binary logistic regression was used to identify potential predictor variables independently associated with the two groups. The covariates' significance was evaluated by the p values (< 0.05) for the association between predictor variables and the possibility of outcome. (lines 176-189)	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	▼	n/a
If data are publicly available, provide accession number in repository or DOI or URL.		n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		n/a

删除的内容: No new data sets.

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	▼	n/a
State whether the code or software is available.		n/a
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a

删除的内容: No new code or software used.

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	▼	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. ▼	

删除的内容: Journal style followed.

删除的内容: The authors have completed the STROBE reporting checklist. (lines 293)

| [Article Information: http://dx.doi.org/10.21037/apm-20-2548](http://dx.doi.org/10.21037/apm-20-2548)